High-Risk MDS
Showing 26 - 50 of >10,000
Leukemia, Myeloid, Acute, MDS, Myelodysplastic Syndrome Acute Myeloid Leukemia Trial in Denver (Nivolumab)
Withdrawn
- Leukemia, Myeloid, Acute
- +2 more
-
Denver, ColoradoColorado Blood Cancer Institute
Apr 20, 2021
MDS Trial in Bronx (Pyrimethamine)
Withdrawn
- Myelodysplastic Syndromes
-
Bronx, New YorkMontefiore Medical Center
Sep 15, 2021
Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Cladribine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)
Active, not recruiting
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Gemtuzumab Ozogamicin
-
Valhalla, New YorkNew York Medical College
Nov 11, 2021
High Risk Myelodysplastic Syndrome Trial in Houston (Guadecitabine)
Active, not recruiting
- High Risk Myelodysplastic Syndrome
-
Houston, TexasM D Anderson Cancer Center
Feb 2, 2022
MDS (MDS), Acute Myelogenous Leukemia (AML) Trial in United States (low dose 5'-azacitidine)
Active, not recruiting
- Myelodysplastic Syndromes (MDS)
- Acute Myelogenous Leukemia (AML)
- low dose 5'-azacitidine
-
Basking Ridge, New Jersey
- +6 more
Dec 1, 2022
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +5 more
- Gemtuzumab Ozogamicin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,
Active, not recruiting
- High Risk Myelodysplastic Syndrome
- +2 more
- Azacitidine
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
Acute Myeloid Leukaemia (AML), MDS (MDS) Trial in Germany, Netherlands (Panobinostat)
Active, not recruiting
- Acute Myeloid Leukaemia (AML)
- Myelodysplastic Syndromes (MDS)
-
Stuttgart, Baden-Württemberg, Germany
- +18 more
Dec 13, 2021
MDS, Progressive Disease Trial in Buffalo, Winston-Salem (CPI-613, Hydroxychloroquine)
Withdrawn
- Myelodysplastic Syndromes
- Progressive Disease
-
Buffalo, New York
- +1 more
Apr 8, 2021
Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Chicago (Laboratory Biomarker
Completed
- Acute Myeloid Leukemia
- +4 more
- Laboratory Biomarker Analysis
- Selinexor
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
May 12, 2021
Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (Nivolumab, Idarubicin, Cytarabine)
Completed
- Leukemia
- +2 more
- Nivolumab
- +4 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 9, 2021
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in Houston (Decitabine and Cedazuridine, Venetoclax)
Recruiting
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Decitabine and Cedazuridine
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndrome Trial in Australia, Netherlands,
Recruiting
- Acute Lymphocytic Leukaemia; Acute Myeloid Leukaemia Refractory; Myelodysplastic Syndrome
-
Duarte, California
- +12 more
Jan 4, 2023
Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia Trial
Recruiting
- Recurrent Chronic Myelomonocytic Leukemia
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2022
Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial
Completed
- Relapsed Acute Myeloid Leukemia (AML)
- +2 more
-
Atlanta, Georgia
- +5 more
Apr 4, 2022
Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Relapsed, Adult, Acute Myelogenous Leukemia, Adult Trial in
Terminated
- Acute Myelogenous Leukemia in Relapse
- +4 more
-
Tucson, Arizona
- +12 more
Aug 18, 2022
Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS Trial in Maywood (Vidaza and Valproic Acid)
Recruiting
- Acute Myelogenous Leukemia AML
- Myelodysplastic Syndrome MDS
- Vidaza and Valproic Acid
-
Maywood, IllinoisLoyola University Cardinal Bernardin Cancer Center
Apr 23, 2021
AML and High Risk MDS Trial in Worldwide (LGH447, LGH447 + midostaurin)
Completed
- AML and High Risk MDS
- LGH447
- LGH447 + midostaurin
-
Ann Arbor, Michigan
- +8 more
Dec 16, 2020
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Newcastle (Bisantrene DiHCl
Recruiting
- Acute Myeloid Leukemia
- +4 more
- Bisantrene Dihydrochloride (high dose)
- +3 more
-
Newcastle, New South Wales, AustraliaCalvary Mater
Jul 14, 2022
Myelodysplasia, Leukemia Trial in Providence (chemo)
Terminated
- Myelodysplasia
- Leukemia
-
Providence, Rhode IslandLifespan Hospitals
Jan 5, 2022